The phase 3 Librexia ACS trial evaluating the safety and efficacy of milvexian after a recent acute coronary syndrome has been discontinued.

Increased odds seen for receiving neurodevelopmental diagnosis by 36 months, especially with third-trimester exposure, among male offspring.

Poherdy can be dispensed as a substitute for Perjeta without requiring a prescription change from a health care provider.

A composite of stroke, systemic embolism, or new covert embolic stroke, occurred in 5 and 9 patients in the rivaroxaban and aspirin groups, respectively.

The FDA requests boxed warnings be removed from HRT product labels; Caplyta approved for MDD; Darzalex Faspro gains new indication; investigational MS treatment looks promising; trial investigates ...

People with high blood pressure were twice as likely to take their blood pressure medication regularly when offered daily chances to win cash rewards, yet it led to similar blood pressure outcomes, ...

The first generic version of conjugated estrogens tablets is now available nationwide in 5 different strengths.

Rates higher among those aged 18 to 21 years, and more than nine in 10 users found the advice somewhat or very helpful.

However, myocardial infarction risk and cerebrovascular accident risk higher in transgender men compared with general population of women ...

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.

The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.

Decrease in mean systolic BP seen for those receiving home-delivered DASH-patterned groceries and dietitian counseling ...